References
- Reece EA, Homko CJ. Why do diabetic women deliver malformed infants?. Clin Obstet Gynecol. 2000; 43: 32–45
- Garner P. Type I diabetes mellitus and pregnancy. Lancet. 1995; 346: 157–61
- Rosenn BM, Miodovnik M. Glycemic control in the diabetic pregnancy: Is tighter always better? (review). J Matern Fetal. 2000; 9: 29–34
- Pregnancy outcomes in the diabetes control and complications trial. Am J Obstet Gynecol. 1996;174:1343–53.
- American Diabetes Association. Preconception care of women with diabetes. Diabetes Care. 2004;27((Suppl 1)):S76–8.
- Barnett AH. A review of basal insulins (see comment) (review). Diabetic Med. 2003; 20: 873–85
- Hirsch IB. Insulin analogues (see comment) (review). N Engl J Med. 2005; 352: 174–83
- Lapolla A, Dalfra MG, Fedele D. Insulin therapy in pregnancy complicated by diabetes: are insulin analogs a new tool? (review). Diabetes Metab Res Rev. 2005; 21: 241–52
- Graves DE, White JC, Kirk JK. The use of insulin glargine with gestational diabetes mellitus. Diabetes Care. 2006; 29: 471–2
- Holstein A, Plaschke A, Egberts EH. Use of insulin glargine during embryogenesis in a pregnant woman with type 1 diabetes. Diabetes Med. 2003; 20: 779–80
- Woolderink JM, van Loon AJ, Storms F, de Heide L, Hoogenberg K. Use of insulin glargine during pregnancy in seven type 1 diabetic women. Diabetes Care. 2005; 28: 2594–5
- Price N, Bartlett C, Gillmer M. Use of insulin glargine during pregnancy: a case-control pilot study. BJOG. 2007; 114: 453–7
- Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabetes Med. 2004; 21: 1213–20
- Devlin JT, Hothersall L, Wilkis JL. Use of insulin glargine during pregnancy in a type 1 diabetic woman. Diabetes Care. 2002; 25: 1095–6
- Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000; 49: 999–1005
- Kitzmiller JL, Main E, Ward B, Theiss T, Peterson DL. Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy. Diabetes Care. 1999; 22: 874–6
- Jovanovic L. Retinopathy risk: What is responsible? Hormones, hyperglycemia, or humalog? Response to Kitzmiller et al. Diabetes Care. 1999; 22: 846–8
- Loukovaara S, Immonen I, Teramo KA, Kaaja R. Progression of retinopathy during pregnancy in type 1 diabetic women treated with insulin lispro. Diabetes Care. 2003; 26: 1193–8